Skip to main content
European Commission logo print header

Diagnosing platform for neurological and mental disorders based on the analysis of ocular and oculocephalic movements.

Objectif

The first product that AURA will launch to the market will be OSCANN, a diagnosis platform that will allow better, faster
and more accurate diagnosis of neurological disorders affecting Europe’s population in general, but specially youngsters
(e.g. ADHD) and elders (e.g. Parkinson). OSCANN allows for the measurement and analysis of ocular and oculocephalic
movements (OM/OCM) and combines the result with data obtained from other sources (clinical histories, medical
explorations, complementary tests and biomarkers) using Artificial Intelligence (AI) techniques to improve significantly the
quality of medical diagnosis in early stages.

Appel à propositions

H2020-SMEInst-2016-2017

Voir d’autres projets de cet appel

Sous appel

H2020-SMEINST-1-2016-2017

Régime de financement

SME-1 - SME instrument phase 1

Coordinateur

AURA INNOVATIVE ROBOTICS, SL
Contribution nette de l'UE
€ 50 000,00
Adresse
CALLE YARUMAL 2 1 A
28045 MADRID
Espagne

Voir sur la carte

PME

L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.

Oui
Région
Comunidad de Madrid Comunidad de Madrid Madrid
Type d’activité
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Liens
Coût total
€ 71 429,00